Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Vertex Pharmaceutic (VRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 44,712,780
  • Shares Outstanding, K 255,560
  • Annual Sales, $ 2,489 M
  • Annual Income, $ 263,480 K
  • 36-Month Beta 1.48
  • Price/Sales 17.97
  • Price/Cash Flow 166.84
  • Price/Book 16.47

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 0.67
  • Number of Estimates 8
  • High Estimate 0.75
  • Low Estimate 0.59
  • Prior Year 0.24
  • Growth Rate Est. (year over year) +179.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
169.33 +3.99%
on 07/26/18
182.34 -3.43%
on 07/18/18
-6.51 (-3.57%)
since 07/17/18
3-Month
144.07 +22.22%
on 06/06/18
183.39 -3.99%
on 07/17/18
+19.74 (+12.63%)
since 05/17/18
52-Week
136.50 +29.00%
on 12/07/17
183.39 -3.99%
on 07/17/18
+27.54 (+18.54%)
since 08/17/17

Most Recent Stories

More News
Lilly (LLY) Hits 52-Week High, Can the Run Continue?

Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

LLY : 105.55 (+1.14%)
VRTX : 176.08 (+0.64%)
BMY : 60.89 (-0.36%)
BIIB : 345.22 (+0.67%)
4 Winning Stocks With Solid Efficiency Level

A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.

SRDX : 73.45 (+0.55%)
ILMN : 325.88 (-0.34%)
VRTX : 176.08 (+0.64%)
MDR : 18.46 (+2.16%)
Should Vertex Pharmaceuticals (VRTX) Be On Your Radar Now?

Vertex Pharmaceuticals (VRTX) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.

VRTX : 176.08 (+0.64%)
Vertex's Cystic Fibrosis Drug Gets FDA Nod for Children

Vertex's (VRTX) cystic fibrosis drug, Kalydeco gets FDA approval to treat children aged 12 months to two years

LGND : 247.98 (+3.47%)
VRTX : 176.08 (+0.64%)
GILD : 72.92 (-3.53%)
BIIB : 345.22 (+0.67%)
FDA Approves KALYDECO(R) (ivacaftor) as First and Only Medicine to Treat the Underlying Cause of CF in Children Ages 12 to <24 Months with Certain Mutations in the CFTR Gene

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved KALYDECO(R) (ivacaftor) to include use in children with cystic...

VRTX : 176.08 (+0.64%)
Bayer Plunges as Monsanto Fined $289M in Roundup Lawsuit

Shares of Bayer (BAYRY) crash as its newly acquired company Monsanto was fined $289 million over allegations that its weedkiller caused cancer.

BAYRY : 22.7300 (+3.98%)
VRTX : 176.08 (+0.64%)
GILD : 72.92 (-3.53%)
SGEN : 74.64 (+0.58%)
Spectrum (SPPI) Earnings and Sales Miss Estimates in Q2

Spectrum (SPPI) reports wider-than-expected loss in the second quarter and misses on revenues. Rolontis successful in second phase III study.

SPPI : 22.78 (-0.26%)
VRTX : 176.08 (+0.64%)
SGEN : 74.64 (+0.58%)
AMGN : 197.42 (+0.50%)
Endo (ENDP) Beats on Q2 Earnings & Sales, Raises Guidance

Endo International (ENDP) gains on better-than-expected Q2 results on the back of growth in demand for Xiaflex and momentum in its Sterile Injectables business.

ENDP : 15.64 (-1.94%)
MRK : 69.06 (+0.31%)
VRTX : 176.08 (+0.64%)
SGEN : 74.64 (+0.58%)
Perrigo (PRGO) Beats on Q2 Earnings, Cuts View, Shares Down

Perrigo (PRGO) reports mixed second-quarter 2018 results and lowers revenue and adjusted earnings guidance for 2018.

MRK : 69.06 (+0.31%)
VRTX : 176.08 (+0.64%)
SGEN : 74.64 (+0.58%)
PRGO : 72.96 (+3.64%)
Sarepta (SRPT) Q2 Loss Narrows, Exondys 51 Drives Sales

Sarepta's (SRPT) loss per share is narrower than the Zacks Consensus Estimate while sales also beat the same. Exondys 51 continues its strong performance.

SRPT : 130.25 (+0.52%)
VRTX : 176.08 (+0.64%)
SGEN : 74.64 (+0.58%)
REGN : 374.26 (+0.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade VRTX with:

Business Summary

Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs...

See More

Key Turning Points

2nd Resistance Point 178.97
1st Resistance Point 177.52
Last Price 176.08
1st Support Level 174.11
2nd Support Level 172.15

See More

52-Week High 183.39
Last Price 176.08
Fibonacci 61.8% 165.48
Fibonacci 50% 159.95
Fibonacci 38.2% 154.41
52-Week Low 136.50

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar